Genmab — Januar 2017
-
Merck`s F&U chef udpeger pipeline juvel i immunterapi / antistofbehandling af kræft. Kandidaten M7824 beskrives som first-in-class bifunktionel immunterapi der blokerer to " immunhæmmende stier " som kræftceller hyppigt bruger til at gemme sig for immunforsvaret. !! -- Hele artiklen er tilgængelig på MedWatch. -Meget spændende.
-
Igen Igen ser vi kæmpehandler i sidste minutter ,, er der nogen der kan forklare mig hvad der sker ,,, ofte er det jo op til 15-20 % af dagsomsætningen der sker der ,,, der må foregå et eller andet
-
Spotlight On: Life after Darzalex – Genmab CEO Jan van de Winkel on how the company's outlook has evolved
Described as a "spectacular success," by Jan van de Winkel, Darzalex could become one of the biggest-selling cancer drugs of all time, predicts the Genmab CEO. He is modest enough to suggest his company is unlikely to discover another therapy with the commercial profile of Darzalex; "these type of products are discovered once every twenty years so it's not realistic to expect us to create a
-
Solsen...må sige du gør meget for dette forum!!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind